Drugs / Terizidone
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/31 trial · 1 met primary | ||||||
| Phase 2/3 | NCT02454205 | Nov 2015 → Dec 2020 | extensively drug-resistant tuberculosis, multidrug-resistant tuberculosis | University of Cape Town | Completed | Met primary |
| Phase 41 trial | ||||||
| Phase 4 | NCT03237182 | Jun 2017 → Dec 2022 | multidrug-resistant tuberculosis | Centre for the AIDS Programme of Research in South Africa | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Terizidone | “cycloserine, terizidone, pretomanid, linezolid” NCT03237182 ↗ |
| Known as | Terizidona | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107553 ↗ |
| Modality | Small molecule | — CHEMBL2107553 ↗ |
| Route | Oral | “Participants will receive six to nine months of oral: Linezolid 600mg daily (reduce to 300mg if toxicity occurs), Bedaquiline 400mg for 2 weeks, followed by 200mg three times...” NCT02454205 ↗ |